Thinly traded nano cap Eyenovia (NASDAQ:EYEN) is up 10% premarket on average volume following its announcement that the FDA has accepted its IND seeking signoff to start a pivotal Phase 3 clinical trial, CHAPERONE, evaluating MicroPine to reduce the progression of myopia (nearsightedness) in children.
The 400-subject study should launch in H1.
MicroPine is a topical microdose formulation of atropine.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.